This is a working overview of Angiotensin IV analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-14 and is reviewed periodically as new material appears.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
While rare, mostly abortive, parthenogenesis is not unknown in birds and eggs can be diploid, automictic and results in male offspring. Birds are solely gonochoric, meaning they have two sexes: either female or male. The sex of birds follows the Z and W sex-determination system, where the ovum determines the sex of the offspring. Male birds have two Z chromosomes (ZZ), and female birds have a W chromosome and a Z chromosome (WZ). In mammals, by contrast, the sperm determines the sex of the offspring in the X and Y sex-determination system. A complex system of disassortative mating with two morphs is involved in the white-throated sparrow Zonotrichia albicollis, where white- and tan-browed morphs of opposite sex pair, making it appear as if four sexes were involved since any individual is compatible with only a fourth of the population. In all species of birds, an individual's sex is determined at fertilisation. One 2007 study claimed to demonstrate temperature-dependent sex determination among the Australian brushturkey, for which higher temperatures during incubation resulted in a higher female-to-male sex ratio. This, however, was later proven to not be the case. These birds do not exhibit temperature-dependent sex determination, but temperature-dependent sex mortality.
== Structure == OpLuc is a complex of two covalently bonded protein subunits: two molecules of 19 kDa and two molecules of 35 kDa components, making it a heterotetrameric molecule. The proteins signal the enzyme for secretion in luminescence, catalyzed by the protein 19 kDa. The luciferase has many cysteine residues that stabilize the enzyme in extracellular environments using disulfide bonds.
== Energy metabolism == Some obligate anaerobes use fermentation, while others use anaerobic respiration. Aerotolerant organisms are strictly fermentative. In the presence of oxygen, facultative anaerobes use aerobic respiration. In the absence of oxygen, some facultative anaerobes use fermentation, while others may use anaerobic respiration.
As opposed to the member states, the relation of EU law and international law is debated, particularly relating to the European Convention on Human Rights and the United Nations. All individual EU member states are party to both organisations through international treaties. The Treaty on European Union article 6(2) required the EU to accede to the ECHR, but would "not affect the Union's competences as defined in the Treaties". This was thought necessary before the Treaty of Lisbon to ensure that the EU gave adequate protection to human rights, overseen by the external European Court of Human Rights in Strasbourg. However, in Opinion 2/13, after a request by the commission to review their plan to accede, the Court of Justice (in Luxembourg) produced five main reasons why it felt that the accession agreement as it stood was incompatible with the treaties. In summary, these were it (1) undermined the CJEU's autonomy (2) allowed for a parallel dispute resolution mechanism among member states, when the treaties said the CJEU should be the sole arbiter (3) the "co-respondent" system, allowing the EU and member states to be sued together, allowed the ECtHR to illegitimately interpret EU law and allocate responsibility between the EU and member states, (4) did not allow the Court of Justice to decide if an issue of law was already dealt with, before the ECHR heard a case, and (5) the ECtHR was illegitimately being given power of judicial review over Common Foreign and Security Policy.
Sources: en.wikipedia.org
In July 2024, Lyme Disease Vaccine Reached Completion of the Primary Series In July 2024, Pfizer and Flagship Pioneering announced an "Innovation Supply Chain" partnership to co-develop 10 drug candidates. Each party committed $50 million upfront, leveraging Flagship's ecosystem of over 40 startups to align with Pfizer's priorities. Pfizer will fund the selected programs and has the option to license or acquire assets, with potential success milestones and royalties reaching up to $700 million per commercialized drug. Two programs, focused on obesity and cardiovascular diseases, have already been initiated. In July 2024, Pfizer advanced its obesity treatment research through the development of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist: In August 2024, Pfizer introduced PfizerForAll, a digital platform designed to streamline access to healthcare and wellness resources in the United States. In October 2024, Pfizer announced positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC. In October 2024, Pfizer announced a partnership with the Ignition AI Accelerator, a collaborative initiative by Nvidia, Tribe, and Digital Industry Singapore (DISG). The collaboration aims using artificial intelligence to expedite drug discovery and development processes, improve operational efficiency, and streamline stakeholder engagement. The initiative also focuses on optimizing manufacturing processes, including improving yields and reducing cycle times.
== In popular culture == Stuntman and comedian Steve-O has publicly spoken of his involvement as a test subject in an early ractopamine study whose aim was to determine the stress limits of ractopamine saturation in humans. Glover says "Based on how dangerous the study was, the more money you get."
=== 31 May === One person was killed by Russian shelling in Vovchansk Raion in Kharkiv Oblast, while three people, including two children, were injured by Russian shelling in Kherson Oblast. One person was also killed by Russian shelling in Donetsk Oblast. Officials in the Russian-installed Luhansk People's Republic said that five people were killed and 19 others were injured after Ukrainian artillery hit a poultry farm. The State Border Guard Service of Ukraine reported that Russian troops had blown up a road that links Ukraine's Chernihiv Oblast with Russia's Bryansk Oblast, saying that the incident occurred at the tripoint between Ukraine, Russia and Belarus. Ukraine claimed that Russian-installed officials in occupied Luhansk were threatening to withhold the wages of workers who refused to open accounts at Russian banks. The Russian defence ministry claimed its forces had pushed out Ukrainian forces from positions around Krasnohorivka and Yasynuvata in Donetsk Oblast. A fire broke out at the Afipsky oil refinery in Russia's Krasnodar Krai. Veniamin Kondratyev, Governor of the region, blamed the fire on a Ukrainian drone strike. The fire was put out with minimal damage and no casualties. Another drone was reported to have crashed into the Ilsky refinery. The governor of Belgorod Oblast announced the beginning of evacuations of children from areas affected by Ukrainian shelling, saying that 300 children would be taken to Voronezh, about 250 km (160 mi) away, while another 1,000 children would be evacuated to other regions over the coming days.
== Awards == 2009 – Bayer Innovators Award; awarded by Bayer New Zealand. 2011 – Supreme Award, Endoform by Mesynthes; awarded by Wellington Gold Awards. 2014 – Fastest Growing Manufacturer; awarded by Deloitte Fast 50. 2015 – New Zealand's Bioscience Company of the Year; awarded by NZBio. 2022 – Most Innovative Dressing or Device, Gold Award; awarded by Journal of Wound Care.
== Cutting == Chainsaws with specially designed bar-and-chain combinations have been developed as tools for use in chainsaw art and chainsaw mills. Specialized chainsaws are used for cutting concrete during construction developments. Chainsaws are sometimes used for cutting ice; for example, ice sculpture and winter swimming in Finland.
Sources: en.wikipedia.org
== Food preparation == Archaeological excavation of ceramic assemblages, pertaining to the Inca, reveal the variety of vessels used in their cuisine. In many excavations, of the ceramic assemblages found, about one tenth tend to be vessels. Ollas were used for cooking, boiling, and stewing, and were essential to Inca cuisine preparation. Ollas were used frequently, since boiling was one of the most repeated food preparation techniques. The vessel is characterized by its wide mouth, with a variety of bases, including the conical-based, round-bottomed, and pedestal-based forms. The Moche, a civilization inhabiting the region before the Inca, elevated olla production by implementing the paddle-and-anvil technique. This technique involved a stone being held on the inside of the vessel, while a wooden paddle was used to form the outside's shape. The practice of the paddle-and-anvil technique added an artistic aspect to the creation of ollas, as the technique provided plenty of flexibility and variation for designing unique vessels. This practice continued into the Inca time period. Other ceramic vessels could be associated with chicha production, which involves its own intricate system of preparation. El Shincal, located in the Argentinian province of Catamarcas, is a chicha production site observed in archaeological studies. Archaeologists have interpreted the purpose of the site as a location that solely caters to feasts and ceremonial events, rather than as a place of permanent settlement.
Continuous glucose monitors (CGMs) are wearable sensors which extrapolate an estimate of the glucose concentration in a patient's blood based on the level of glucose present in the subcutaneous interstitial fluid. A thin, biocompatible sensor wire coated with a glucose-reactive enzyme is inserted into the skin, allowing the system to read the voltage generated, and based on it, estimate blood glucose. The biggest advantage of a CGM over a traditional fingerstick blood glucose meter is that the CGM can take a new reading as often as every 60 seconds (although most only take a reading every 5 minutes), allowing for a sampling frequency that is able to provide not just a current blood sugar level, but a record of past measurements; allowing computer systems to project past short-term trends into the future, showing patients where their blood sugar levels are likely headed.
Ring strain and electron deficiency in the oxanorbornadiene increase reactivity towards the cycloaddition rate-limiting step. The retro-Diels Alder reaction occurs quickly afterwards to form the stable 1,2,3 triazole. Problems include poor tolerance for substituents which may change electronics of the oxanorbornadiene and low rates (second order rate constants on the order of 10−4).
=== Response duration === The response duration is occasionally used to analyze the results of the treatment for the advanced disease. The event is progression of the disease (relapse). This endpoint involves selecting a subgroup of the patients. It measures the length of the response in those patients who responded. The patients who don't respond aren't included.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.